Dual-Tracer PET/CT Imaging in Evaluation of Metastatic Hepatocellular Carcinoma

Chi-lai Ho, Sirong Chen, David W.C. Yeung, and Thomas K.C. Cheng

Department of Nuclear Medicine and PET, Hong Kong Sanatorium and Hospital, Hong Kong, China

We have reported previously that 11C-acetate (11C-ACT) PET was complementary to 18F-FDG PET in the evaluation of primary hepatocellular carcinoma (HCC) in relation to the degree of tumor cellular differentiation. In this retrospective study, our goals were to further explore the complementary role of 11C-ACT and 18F-FDG PET in the detection of metastatic HCC disease, to evaluate the tracer characteristics of individual organ metastasis, to identify the risk factors of metastasis, and to evaluate how these results could affect patient management. Methods: One hundred twenty-one patients were selected for this study. All patients had undergone a “dual-tracer” PET/CT same-day protocol with 11C-ACT PET/CT followed by 18F-FDG PET/CT. Sets of criteria were chosen to define “metastasis” and “no metastasis” on a patient basis. The patients considered as true-positive (n = 97) were then divided into 4 groups on the basis of their primary HCC tracer avidity: 18F-FDG-avid group, 11C-ACT-avid group, 18F-FDG- and 11C-ACT-avid group, and a posttreatment group with metastasis but no baseline dual-tracer PET characterization of the primary tumor and no hepatic recurrence. Results: On a patient basis, dual-tracer PET/CT had a sensitivity of 98%, a specificity of 86%, a positive predictive value of 97%, a negative predictive value of 90%, and an accuracy of 96% in the detection of HCC metastasis. On a lesion basis, 273 metastatic HCC lesions considered as true-positive were detected and categorized according to the organ or site of metastasis: lymph node (abdominal and thoracic, 49%), lung (32%), bone (8%), and others (10%). The lesion-based and patient-based detection sensitivities were 60% and 64%, respectively, by 11C-ACT and 77% and 79%, respectively, by 18F-FDG, and they were complementary. In analyzing lesion tracer avidity, there was a positive statistical correlation between primary HCC avidity with the general tendency of metastasis. Clinically significant changes in management were found in patients with true-positive metastasis, of whom 19% were affected by 11C-ACT PET alone. Dual-tracer PET/CT was more effective than single-tracer PET/CT in identifying candidates for curative therapy (negative predictive value of dual-tracer, 18F-FDG, and 11C-ACT PET/CT: 90%, 49%, and 37%, respectively). Conclusion: This study confirmed that 18F-FDG PET/CT is useful in the evaluation of HCC metastasis, although its role in the diagnosis of primary HCC is more limited. Dual-tracer PET/CT had an incremental value and complementary advantage when compared with single-tracer imaging in the evaluation of HCC metastasis.

Key Words: 11C-acetate; 18F-FDG; PET/CT; hepatocellular carcinoma; metastasis

DOI: 10.2967/jnumed.106.036673

It is known that 18F-FDG PET is not sensitive enough for the diagnosis of primary hepatocellular carcinoma (HCC) (1–3). Although there are limited data on the role of 18F-FDG PET in the detection of HCC metastasis, these reports suggest that 18F-FDG PET could be useful in the evaluation of extrahepatic metastasis, despite its limited role in the primary diagnosis of HCC (4–8).

We have reported previously that another PET tracer, 11C-acetate (11C-ACT), was complementary to 18F-FDG in the detection of primary HCC (1,9). The HCC tumors that were not evident with 18F-FDG were detected by 11C-ACT. The pattern of tracer uptake by the tumors was correlated with tumor cellular differentiation. The well-differentiated HCCs preferentially accumulate 11C-ACT, whereas the poorly differentiated tumors tend to be 18F-FDG avid. In evaluating malignant lesions in the liver, the 11C-ACT tracer was quite specific for HCC, as this tracer was not accumulated in pure cholangioadenocarcinoma and metastatic liver tumors from various primary malignancies. Therefore, the combined use of 11C-ACT and 18F-FDG—the so-called “dual-tracer” PET or PET/CT protocol—has been used in this center since 2000 to evaluate patients with known HCC or suspicious liver masses.

In this retrospective study, we proposed the use of the same dual-tracer protocol for the evaluation of HCC metastasis. The goals of this research were to evaluate the detection sensitivity of metastatic HCC lesions with both 11C-ACT and 18F-FDG, compared with that of 18F-FDG alone; to perform analysis on the dual-tracer uptake pattern of the metastatic lesions and their organs or sites of metastatic involvement; and to correlate these results with clinical outcome in terms of their usefulness in affecting subsequent patient management.

MATERIALS AND METHODS

Patient Selection and Study Criteria

We reviewed all patients referred to this center from 2002 to 2006 for dual-tracer (11C-ACT and 18F-FDG) PET/CT...
evaluation of liver masses. Only those patients with confirmed primary HCC malignancy (by histopathology or by Barcelona criteria (10)) and no other clinical suspicion of second cancers were included. On the basis of the availability and reliability of follow-up information, 121 patients (96 men, 25 women; age range, 16–81 y; mean age, 58.6 ± 12.7 y [mean ± SD]) were included in the study population. Eighty-one patients were positive for hepatitis B surface antigen, and 4 patients were positive for hepatitis C.

Confirmation of Metastasis. Because histopathologic confirmation of metastasis was not possible in all patients or in all lesions, a set of criteria was designed to include other clinical, biochemical, and imaging parameters as objective evidence that a lesion detected by PET/CT was most likely a metastasis. A lesion satisfying 1 or more of the following criteria was considered a metastasis: (a) histopathologic confirmation of metastasis by resection or biopsy, (b) biochemical evidence of increasing α-fetoprotein concentration and clinical follow-up, (c) 2 or more serial PET/CT studies in a 3- to 7-mo period with unequivocal evidence of progression, and (d) additional or follow-up radiologic evidence of bone and lung metastases (evidence of bone destruction, increase in number and size of satellite lung nodules with no clinical evidence of infection).

Confirmation of No Metastasis. A patient satisfying all the following criteria was considered to be without metastasis: (a) diagnosis as having no extrahepatic or intravascular metastasis by pretreatment dual-tracer PET/CT, (b) primary HCC tumors completely resected, and (c) follow-up PET/CT and other diagnostic studies showing no extrahepatic metastasis in a 5- to 18-mo follow-up interval (median, 11 mo).

The true-positive (TP) patients were then divided into 4 groups on the basis of their primary HCC tracer avidity: group I, 18F-FDG avid; group II, 11C-ACT avid; group III, 18F-FDG and 11C-ACT avid; and group IV, patients with extrahepatic metastasis in whom the primary tumor tracer avidity was not evaluable because their primary HCC was resected or ablated before PET/CT evaluation and no hepatic recurrence was found.

Criteria Used to Determine a Change in Management. The patients referred for initial staging were originally scheduled for curative resection if PET/CT was negative for metastasis. Therefore, for these patients, any positive evidence of metastasis found by PET/CT was considered to lead to a change in management if the patient did not go for surgery or ablation of the primary HCC or the patient underwent resection or ablation of both the primary tumor and metastatic foci. For patients who were referred for restaging, a positive PET/CT finding that led to further treatment was considered a change in management. For patients who were initially judged as having metastasis by radiologic findings, a negative PET/CT finding, which convinced the surgeons to undertake surgery, that confirmed no metastasis was also considered a change in management.

This study was approved by the Ethics and Research Committee of the authors’ clinical institution for investigation of primary HCC, and all patients gave informed and written consent before the imaging procedure was undertaken. Analysis of the data for metastatic HCC was subsequently retrospective. The patients had fasted for at least 6 h and the blood glucose concentration was determined before injection of PET radiopharmaceuticals. All patients except 2 had glucose concentrations below 7 mmol/L. Both hyperglycemic patients (with blood glucose of 8.1 and 8.5 mmol/L) were given 2 units of short-acting insulin intravenously and waited for 1 h after confirmation of normoglycemic status before injection of PET radiopharmaceuticals.

Dual-Tracer PET/CT

11C-ACT was prepared by modifying the methodology and setup as reported by Norenberg (11). 11C-ACT (550–740 MBq) was administered intravenously, and imaging of the whole-body was performed at 20 min after injection using an integrated in-line PET/CT scanner (Biograph lutetium oxyorthosilicate [LSO] or Biograph 16 LSO HI-REZ; Siemens Medical Solutions USA, Inc.). Data acquisition began with CT (with no contrast agent) at 130 kVp, 110–115 mA, 2-mm pitch, and 1-s tube rotation; this was followed by PET with a 2-min emission acquisition time of 47 (Biograph) or 81 (Biograph 16) axial image planes simultaneously at a 16.2-cm axial field of view per position. The images were reconstructed by means of the standardized ordered-subset expectation maximization (OSEM) technique using 8 subsets and 2 iterations with a 128 × 128 matrix (Biograph) or 168 × 168 matrix (Biograph 16) for PET and a 512 × 512 matrix for CT. The average reconstructed x–y spatial resolution for PET was about 3.5-mm full width at half maximum in-plane (at 1 cm).

About 15 min after 11C-ACT imaging, 18F-FDG (370–550 MBq) was injected intravenously (about 45 min after initial 11C-ACT injection). Scanning with the same imaging positions and acquisition settings of the whole-body or upper abdomen began at 60 min after 18F-FDG administration. This allowed a total of about 105 min after initial injection of 11C-ACT, >5 decay half-lives of 11C (20 min). Attenuation correction, reconstruction parameters, and semiquantitative analysis were similar to the specifications as stated earlier.

Interpretation Criteria and Statistical Analysis

A lesion was regarded as positive for metastasis on the basis of visual judgment of the degree of increased metabolism by 3 experienced and independent interpreters, supported by semiquantitative evaluation based on calculation of the standardized uptake value (SUV) in both sets of 11C-ACT PET. Both maximum (SUVmax) and average (SUVavg) SUVs were calculated. A SUVmax > 2.0 was generally used as the semiquantitative criterion of metastasis in both 18F-FDG and 11C-ACT PET. The McNemar test was adopted to compare the avidity difference between 18F-FDG and 11C-ACT PET/CT. Group comparisons of tracer avidity differences were tested for significance using the χ² test. If serial PET/CT studies persistently did not show increased metabolism and size by either tracer, the lesions seen on CT (particularly enlarged abdominal lymph nodes) were regarded as negative for metastasis. If >3 metastatic lesions of lung or bone were seen, these were counted as 3 lesions maximum. This was done to avoid bias of statistical counting by one or a few patients presenting with an advanced stage of metastasis with numerous metastatic lung or bone lesions. Metastatic lymph nodes were counted in accordance with location. Peritoneal and omental lesions were classified as soft-tissue metastasis because of their small number and for simplicity of data analysis.

A “TP” case was defined as follows: Single- or dual-tracer PET/CT correctly detects at least 1 metastasis (regardless of the accuracy of the other metastatic lesions) in a patient who truly has metastasis and is thus not a candidate for curative therapy. A “true-negative” (TN) case was defined by the usual convention that single- or dual-tracer PET/CT correctly identifies a patient who truly had no metastasis.
RESULTS

Patient-Based Analysis

Among the 121 patients, 21 were diagnosed as having no metastasis by dual-tracer PET/CT. The follow-up period of this control group was 5–18 mo (median, 11 mo). During this period, 19 patients who satisfied the preset criteria of having no metastasis remained well by clinical, biochemical, and follow-up PET/CT. One FN patient had multiple metastatic mediastinal nodes that initially showed very minimal to no $^{11}$C-ACT and $^{18}$F-FDG activity on preoperative PET/CT. After 2 serial imaging studies (5 mo later), most of the mediastinal nodes began to show increased $^{11}$C-ACT metabolism and enlargement with progressively rising $\alpha$-fetoprotein concentration but without primary tumor recurrence in liver. The other FN patient had a markedly elevated $\alpha$-fetoprotein concentration and multiple $^{18}$F-FDG- and $^{11}$C-ACT-avid lung nodules on follow-up PET/CT 7 mo after primary HCC resection. Retrospective review of the baseline PET/CT showed that 2 subcentimeter lung nodules could have been faintly present on CT but had no abnormal $^{18}$F-FDG or $^{11}$C-ACT uptake.

One hundred patients diagnosed by dual-tracer PET/CT had metastasis. Among them, 97 patients satisfied the preset criteria of metastasis. The follow-up period of serial PET/CT was 3–7 mo (median, 4 mo). The 3 false-negative (FN) cases with 7 lung lesions were faintly seen on CT. They were all mildly $^{18}$F-FDG avid and either resolved on subsequent follow-up PET/CT or remained static without increased serum $\alpha$-fetoprotein levels.

On a patient basis, dual-tracer PET/CT had a sensitivity of 98% (97/99), a specificity of 86% (19/22), a positive predictive value (PPV) of 97% (97/100), and an accuracy of 96% (116/121) in the detection of HCC metastasis (Table 1). The corresponding data for single-tracer PET/CT (based on the criteria defined earlier) are also summarized in Table 1. The patient-based sensitivities of $^{18}$F-FDG and $^{11}$C-ACT PET/CT were 79% and 64%, respectively. However, the NPV was <50% when using either tracer alone. This implies that negative single-tracer PET/CT may not be sufficient to choose the correct candidate for curative therapy in view of the high FN rate in the detection of HCC metastasis.

<table>
<thead>
<tr>
<th>Tracer</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
<th>PPV (%)</th>
<th>NPV (%)</th>
<th>Accuracy (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>$^{18}$F-FDG*</td>
<td>79 (78/99)</td>
<td>91 (20/22)</td>
<td>98 (78/80)</td>
<td>49 (20/41)</td>
<td>81 (98/121)</td>
</tr>
<tr>
<td>$^{11}$C-ACT*</td>
<td>64 (63/99)</td>
<td>95 (21/22)</td>
<td>98 (63/64)</td>
<td>37 (21/57)</td>
<td>69 (84/121)</td>
</tr>
<tr>
<td>Dual-tracer</td>
<td>98 (97/99)</td>
<td>86 (19/22)</td>
<td>97 (97/100)</td>
<td>90 (19/21)</td>
<td>96 (116/121)</td>
</tr>
</tbody>
</table>

*Definition of TP for single-tracer PET/CT: correct detection of at least 1 metastatic lesion in a patient with metastatic HCC disease.
Detection Analysis According to Primary HCC Tracer Avidity

Of the 110 metastatic lesions detected by $^{18}$F-FDG, 62 lesions detected by $^{11}$C-ACT, and 101 lesions detected by both tracers, each category of these metastatic lesions was further classified according to the grouping method as indicated earlier (according to tracer avidity of their primary HCC tumors). The results are summarized in Table 3.

In group I, there were 41 metastatic lesions. Of these 41 lesions (6 lesions avid for both tracers), $^{18}$F-FDG detected 36 (88%) and $^{11}$C-ACT detected 11 (27%) ($P < 0.05$, McNemar test). The 12% metastatic lesions that were negative on $^{18}$F-FDG were detected by $^{11}$C-ACT. In this group of patients, the most frequent site of metastasis was the lymph nodes (27/41 lesions, 66%).

In group II, there were 43 metastatic lesions. Of these 43 lesions (12 lesions avid for both tracers), $^{18}$F-FDG detected 29 (67%) and $^{11}$C-ACT detected 26 (60%) ($P < 0.05$, McNemar test). This implied that the use of either tracer alone would have a 30%–40% FN detection rate of metastasis in this group of patients. However, these 2 tracers were complementary to each other as in group I, with all of the metastatic lesions detected by the combination of both tracers. This group of patients had the highest incidence of detection in lung-pleura metastasis (25/43 lesions, 58%).

In group III, there were 122 metastatic lesions. With 44 lesions avid for both tracers, $^{18}$F-FDG detected 95 lesions (78%) and $^{11}$C-ACT detected 71 lesions (58%) ($P < 0.05$, McNemar test). Lymph node metastasis (thoracic plus abdominal) had the highest incidence in this group of patients (68/122 lesions, 56%).

In group IV, the group without primary HCC recurrence, there were 67 metastatic lesions (39 lesions avid for both tracers). $^{18}$F-FDG detected 51 (76%) and $^{11}$C-ACT detected 55 (82%). Although the difference was not statistically significant ($P > 0.05$, McNemar test), this was the only group of patients with the detection sensitivity higher using $^{11}$C-ACT than that using $^{18}$F-FDG. Statistically, it was also significantly higher than the $^{11}$C-ACT detection sensitivity in the other 3 groups ($P < 0.05$ for group I, $P < 0.05$ for group II, $P < 0.05$ for group III; $\chi^2$ test). Lung-pleura was the organ or site with the highest rate of metastasis (32/67 lesions, 48%). Of these 32 lesions, $^{11}$C-ACT detected 29 (91%) and $^{18}$F-FDG detected 18 (56%) ($P < 0.05$, McNemar test), indicating that $^{11}$C-ACT is the more important tracer in this group of patients in the detection of lung metastasis.

A summary of the individual tracer detection sensitivities for all 4 groups of patients is given in Table 4.

Results of Individual Organ Metastasis According to Tracer Avidity

Further breakdown of the organ metastasis according to tracer avidity is also summarized in Table 3, which shows that $^{18}$F-FDG was better than or equal to $^{11}$C-ACT in identifying metastatic lesions in each of the organ categories. $^{18}$F-FDG alone detected 78% (105/135) of the metastatic lymph nodes, 75% (66/88) of lung-pleura...
lesions, 83% (19/23) of bone metastases, 83% (15/18) of vascular metastases, and 67% (6/9) of adrenal and soft-tissue metastases. $^{11}$C-ACT alone detected 56% (76/135) of the metastatic lymph nodes, 64% (56/88) of lung-pleura lesions, 70% (16/23) of bone metastases, 50% (9/18) of vascular metastases, and 67% (6/9) of adrenal and soft-tissue metastases. These data showed that the complementary relationship between these 2 tracers was also found in the detection of metastasis similar to that noted previously in the primary HCC (1,9).

Change in Patient Management

Of the 97 patients with metastasis, 47 patients (48%) had evaluation during their first presentations and were not known to have metastasis before imaging. Figure 1 summarizes the change in management as a result of the dual-tracer PET/CT findings. After PET/CT, 36 patients chose to have no further treatment or some form of alternative treatment. They all died after a median survival of <1 y and avoided unnecessary surgery that would not have lengthened their survival. Eight patients chose to undergo chemotherapy or focused radiation therapy. One patient was successfully down-staged on the basis of serial follow-up PET/CT and subsequently underwent resection of her primary HCC tumor. She was alive at 18 mo of follow-up. Three of the 47 patients had their primary and secondary tumors (single-organ metastasis) resected in one operation.

Similarly, the remaining 50 patients with previous treatments who were found to have metastasis by dual-tracer PET/CT were also given different forms of treatment or no treatment on the basis of the PET/CT findings. Twenty-three patients died within 1 y without treatment, 18 patients had chemotherapy or radiation therapy (2 of whom were down-staged for surgery on the basis of the serial follow-up PET/CT), and 9 patients had surgical resection of metastasis (Fig. 1).

Of the 19 TN patients, 3 with cirrhosis had abdominal lymphadenopathy initially diagnosed as metastasis by CT/MRI. Benign enlargement of abdominal nodes is frequently found in cirrhotic patients (12). These 3 patients underwent curative resection after dual-tracer PET/CT revealed negative findings. The lymph nodes were confirmed as negative for metastasis either intraoperatively or by histopathologic examination, and follow-up over 5–18 mo showed no evidence for extrahepatic metastasis.

### Table 4

<table>
<thead>
<tr>
<th>Group</th>
<th>$^{18}$F-FDG Sensitivity (%)</th>
<th>$^{11}$C-ACT Sensitivity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>88 (36/41)</td>
<td>27 (11/41)</td>
</tr>
<tr>
<td>II</td>
<td>67 (29/43)</td>
<td>60 (26/43)</td>
</tr>
<tr>
<td>III</td>
<td>78 (95/122)</td>
<td>58 (71/122)</td>
</tr>
<tr>
<td>IV</td>
<td>76 (51/67)</td>
<td>82 (55/67)</td>
</tr>
</tbody>
</table>

### Discussion

The nature and characteristics of HCC metastasis have not been described in detail in the literature. Presumably, one of the major reasons is that this is not a common type of cancer in the Euro-American population. Furthermore, it has been suggested that conventional methods of imaging are somewhat insensitive for staging HCC (13). The existing data on conventional and nonconventional methods for evaluation of HCC metastasis are scarce in the literature. CT is the standard tool for conventional imaging (14), which is based primarily on the assumption that most HCC tumors—primary and metastatic—are hypervascular, and the arterial phase should demonstrate increased contrast enhancement within the lesion. With today’s multidetector and high-resolution technology, CT is particularly useful for evaluation of small lesions.
and determination of the spatial relationship between the tumor and the background normal tissue architecture. However, the increased sensitivity may likely result in over-diagnosis of some other hypervascular tumor or tumor-like lesions, particularly when they are small in size (15). On the other hand, differentiation between recurrence and posttreatment scarring changes and between metastasis and reactive lymph node enlargement are less effective using CT alone. Detection of osseous metastatic disease is another known limitation of CT, as most metastatic bone lesions from HCC are osteolytic (16,17) and are evident on CT only as a late manifestation.

In recent years, 18F-FDG PET and PET/CT are increasingly important tools for tumor staging. Despite the fact that 18F-FDG PET has only a fair sensitivity in diagnosis of the primary HCC tumor, Sugiyama et al. (6) and Bohm et al. (4) have reported that 18F-FDG PET may have incremental value in detection of HCC secondary tumors. The detection sensitivities were 83% and 64%, respectively. Chen et al. (5) showed that 18F-FDG PET identified the source of elevated α-fetoprotein in 73% of their patients after treatment of HCC. Wudel and Delbeke’s group (8) also showed that 18F-FDG PET affected management in 28% of a group of 91 HCC patients, including a subgroup with extrahepatic metastasis. In our study, using 18F-FDG alone, PET/CT had a patient-based sensitivity of 79% and a lesion-based sensitivity of 77%. These sensitivities were closer to the value of Sugiyama et al. than those of Bohm et al. However, when the lesion-based sensitivity was further categorized in individual groups (Table 4), 18F-FDG had the highest sensitivity (88%) in the detection of HCC metastasis when the primary HCC tumor was also 18F-FDG avid. On the other hand, when the primary HCC was 11C-ACT avid, 18F-FDG had the lowest sensitivity (67%). Thus, the sensitivity of 18F-FDG PET in detecting metastatic lesions is dependent on the avidity of the primary tumor tracer, which reflects the degree of cellular differentiation of the primary HCC tumor. These 2 values are individually comparable with those reported by Sugiyama et al. and Bohm et al., but whether the difference had any relation to the differentiation of the primary HCC is uncertain.

Our study is different from those of Sugiyama et al. (6) and Bohm et al. (4) in the use of 2 PET tracers instead of one. In our 4 groups of patients, the relative FN rate of 18F-FDG PET was 12%–33%; however, the undetected lesions could be detected by 11C-ACT PET. In other words, the complementary nature of 11C-ACT and 18F-FDG is evident not just in primary HCC tumors (1,9) but also in metastatic HCC lesions. Furthermore, patient management decisions were largely based on the dual-tracer PET/CT findings in our institution. The incremental value of 11C-ACT PET relative to that of 18F-FDG PET alone is difficult to quantify, as the patients with metastatic HCC are a heterogeneous group of patients often with multiorgan and multifocal involvement. Among the 97 patients, 18 patients (19%) had single- or multiorgan metastases avid for 11C-ACT only. On a lesion basis, 23% of metastatic lesions were detected by 11C-ACT only. These results suggest that the incremental value of 11C-ACT PET in affecting patient management is significant. Individually, 11C-ACT PET may have greater impact on the group II and group IV patients, particularly in those cases with single-organ metastasis.

The NPV of PET/CT with either single tracer was <50% on a patient basis (Table 1). This implies that a negative single-tracer study cannot reliably exclude metastatic HCC and, therefore, single-tracer PET/CT is not an accurate tool in identifying candidates for curative therapy. However, with dual-tracer PET/CT, the NPV increased significantly to 90% (19/21). The FN cases with dual-tracer PET/CT were patients with tiny lung lesions and mediastinal nodes of <1 cm with either equivocal or minimally increased uptake of either tracer. This is a known technical limitation of PET/CT, related to partial-volume effects and respiratory motion.

**Primary HCC Features Affecting Likelihood of Metastasis**

From the results in this study and 2 earlier studies (1,9), we have identified 3 separate groups of HCC patients who have (a) a small primary tumor with a size of 1.4 ± 0.3 cm and no metastasis, (b) an intermediate primary tumor with a size of 3.5 ± 1.9 cm and no metastasis, and (c) HCC with metastasis (this study). As summarized in Table 5, there is a steady increase in the percentage of primary tumors that are avid for 18F-FDG, from 32% to 80%, whereas the percentage for 11C-ACT remained stable at 83%–87%. Because individual tracer avidity was related to cellular differentiation in HCC, one could speculate that it is more likely for metastasis to occur in cases of primary HCC tumors with poor differentiation than for those with well-differentiated pathology.

Another group of patients of special interest is group IV, where no recurrence was found in the liver previously treated for primary HCC but where there were extrahepatic metastases. This group of patients had the highest metastasis detection sensitivity (82%) by 11C-ACT, quite similar to that of the primary HCC tumors of this study (83% by 11C-ACT) and the 2 earlier studies (87% by 11C-ACT) (1,9). Therefore, unlike the other 3 groups, 11C-ACT PET is the more important tracer in this group of patients for the detection of metastasis.

**TABLE 5**

Comparison of 18F-FDG and 11C-ACT in Detection Sensitivities of Primary HCC Tumor

<table>
<thead>
<tr>
<th>Primary HCC group</th>
<th>18F-FDG (%)</th>
<th>11C-ACT (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Small (no metastasis)</td>
<td>32 (12/38)</td>
<td>87 (33/38)</td>
</tr>
<tr>
<td>Intermediate (no metastasis)</td>
<td>47 (26/55)</td>
<td>87 (48/55)</td>
</tr>
<tr>
<td>HCC with metastasis</td>
<td>80 (60/75)</td>
<td>83 (62/75)</td>
</tr>
</tbody>
</table>
Individual Organ Metastasis

Our data show that lung metastases constitute the largest group of metastatic lesions, followed by metastases to abdominal lymph nodes, thoracic lymph nodes, bone, and other sites in descending order of prevalence. Excluding the thoracic nodes, these results are similar to those found in the literature (14,18). However, our data also suggest that thoracic nodal involvement constitutes a significant site of organ metastasis (63 thoracic nodes, 72 abdominal nodes). Lymphatic spread from the liver, as one of the upper gastrointestinal malignancies, follows a specific pathway of drainage through the lesser omentum to the retroperitoneal space, to the hepatoduodenal, peripancreatic, and aortocaval nodes (19). Lymphatic spread may also ascend within the retroperitoneal space along the aortocaval chain to the subphrenic and thoracic nodal basins. As a result, the metastatic thoracic nodes that have been observed in this study include the paravertebral, paraesophageal, subcarinal, and precarinal nodes and other less common sites in the mediastinum. When these nodes are 11C-ACT avid, it is more likely that they truly harbor HCC metastasis. However, because biopsy of all suggestive lesions was not always possible, a small number of these intrathoracic nodes with increased 18F-FDG activity could be noncalcified.

FIGURE 2. Mediastinal metastasis: a 49-y-old patient who had right hemihepatectomy for HCC 3 y earlier. Follow-up chest radiographs showed a right middle lobe (RML) mass. 18F-FDG and 11C-ACT PET/CT showed hypermetabolic RML lung mass and large precarinal node (arrows). Biopsy confirmed metastatic HCC pathology in both locations.

FIGURE 3. Multifocal bone metastases: a 62-y-old patient with previous liver resection for HCC. 18F-FDG and 11C-ACT PET/CT showed multifocal lung and bone metastases. Note that 11C-ACT revealed more bone metastasis than 18F-FDG (e.g., right humeral and thoracic lesions [small arrows]), and 11C-ACT lesions are significantly more intense. Largest left iliac lesion (large arrows) showed typical osteolytic pattern on CT bone window.
granulomatous nodes and, thus, be FP for metastasis. This possibility was minimized by correlation with serial PET/CT and other ancillary findings, such as concomitant biopsy-proven metastatic lung nodules (Fig. 2) and clinical follow-up.

The detection of bone metastasis showed no significant difference between $^{18}$F-FDG and $^{11}$C-ACT (12 vs. 10 patients, respectively, in 15 patients with metastatic bone disease). However, unrevealed by the statistics, the metastatic bone lesions avid for both tracers were usually more avid for $^{11}$C-ACT than for $^{18}$F-FDG (Fig. 3).

**Limitations**

As in many retrospective studies, the histopathologic confirmation of metastatic lesions is not always possible, particularly in patients with multiple sites or organs of involvement, multiple lesions, small lesions, bone lesions, or lesions in locations where biopsy is difficult or risky. Fortunately, most patients in our study had a high pretest probability of metastasis and many had serial imaging studies for comparison; thus, the likelihood of conflicting statistics was small. Another limitation of this study is the difficulty in statistical analysis on a patient basis, because a single patient could have multiple coexisting metastatic lesions with different tracer avidities. Therefore, the statistics on a lesion basis should be more reliable for practical purposes.

**CONCLUSION**

Accurate assessment of metastasis, staging, and therapy of HCC requires a precise imaging tool. The current study confirms that $^{18}$F-FDG PET alone has a reasonable sensitivity in the detection of HCC metastasis, although it is not sensitive enough for the evaluation of HCC primary tumor. This study has focused on the PET/CT evaluation of metastatic HCC with a dual-tracer protocol ($^{11}$C-ACT and $^{18}$F-FDG), and our results suggest that it has a mutual complementary advantage, similar to the conclusion found previously in the detection of primary HCC tumors.

**ACKNOWLEDGMENTS**

The authors express their sincere gratitude to Dr. Shiu Man Hee of the Department of Surgery and Dr. Thomas Leung of the Department of Oncology, Hong Kong Sanatorium and Hospital, for their valuable suggestions.

**REFERENCES**

Dual-Tracer PET/CT Imaging in Evaluation of Metastatic Hepatocellular Carcinoma

Chi-lai Ho, Sirong Chen, David W.C. Yeung and Thomas K.C. Cheng

Published online: May 15, 2007.
Doi: 10.2967/jnumed.106.036673

This article and updated information are available at:
http://jnm.snmjournals.org/content/48/6/902

Information about reproducing figures, tables, or other portions of this article can be found online at:
http://jnm.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNM can be found at:
http://jnm.snmjournals.org/site/subscriptions/online.xhtml